Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immunogen Inc
(NQ:
IMGN
)
31.25
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunogen Inc
< Previous
1
2
3
4
5
Next >
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
October 29, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results
October 14, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors
September 22, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
July 30, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results
July 15, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
May 20, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status
May 19, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results
May 10, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2021 Operating Results
April 26, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting
April 10, 2021
From
ImmunoGen Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.